WE CLAIM:

1. A method for diagnosing a cancer in a mammal, comprising:

detecting and measuring the WIP1 gene copy number in a biological subject from a region of the mammal that is suspected to be precancerous or cancerous, thereby generating data for a test gene copy number; and

comparing the test gene copy number to data for a control gene copy number, wherein an amplification of the gene in the biological subject relative to the control indicates the presence of a precancerous lesion or a cancer in the mammal.

2. The method according to claim 1, wherein the biological subject is selected from the group consisting of breast tissue, lung tissue, prostate tissue, ovarian tissue, and colon tissue.

3. The method according to claim 1, wherein the data is stored in an electronic or a paper format, wherein the electronic format is selected from the group consisting of electronic mail, disk, compact disk (CD), digital versatile disk (DVD), memory card, memory chip, ROM or RAM, magnetic optical disk, tape, video, video clip, microfilm, internet, shared network, shared server; wherein the data is displayed, transmitted or analyzed via physical transfer, electronic transmission, video display, or telecommunication; wherein the data is compared and compiled at the site of sampling specimens or at a location where the data is transmitted.

4. A method for inhibiting cancer or precancerous growth in a mammalian tissue, comprising contacting the tissue with a nucleotide molecule that interacts with WIP1 DNA or RNA and thereby inhibits WIP1 gene function.

5. The method according to claim 4, wherein the nucleotide molecule is an antisense nucleotide.

6. The method according to claim 4, wherein the nucleotide molecule is a ribozyme.

7. The method according to claim 4, wherein the nucleotide molecule forms a triple helix with a WIP1-encoding nucleic acid.

8. The method according to claim 4, wherein the tissue is selected from the group consisting of breast tissue, lung tissue, prostate tissue, ovarian tissue, and colon tissue.

9. A method for monitoring the efficacy of a therapeutic treatment regimen in a patient, comprising:

measuring the WIP1 gene copy number in a first sample of precancerous or cancer cells obtained from a patient;

administering the treatment regimen to the patient;

measuring the WIP1 gene copy number in a second sample of precancerous or cancer cells from the patient at a time following administration of the treatment regimen; and

comparing the gene copy number in the first and the second samples, wherein data showing a decrease in the gene copy number levels in the second sample relative to the first sample indicates that the treatment regimen is effective in the patient.

10. The method according to claim 9, wherein the precancerous or cancer cells are obtained from breast tissue, lung tissue, prostate tissue, ovarian tissue, and colon tissue.

11. The method according to claim 9, wherein the data from measuring or comparing the expression levels is stored in an electronic or a paper format, wherein the electronic format is selected from the group consisting of electronic mail, disk, compact disk (CD), digital versatile disk (DVD), memory card, memory chip, ROM or RAM, magnetic optical disk, tape, video, video clip, microfilm, internet, shared network, shared server; wherein the data is displayed, transmitted or analyzed via physical transfer, electronic transmission, video display, or telecommunication; wherein the data is compared and compiled at the site of sampling specimens or at a location where the data is transmitted.

12. A method for diagnosing a cancer in a mammal, comprising:

measuring the level of WIP1 mRNA transcripts in a biological subject from a region of the mammal that is suspected to be precancerous or cancerous, thereby generating data for a test level; and

comparing the test level to data for a control level, wherein an elevated test level of the biological subject relative to the control level indicates the presence of a cancer or precancerous lesion in the mammal.

13. The method according to claim 12 wherein the biological subject is selected from the group consisting of breast tissue, lung tissue, prostate tissue, ovarian tissue, and colon tissue.

14. The method according to claim 12, wherein the data is stored in an electronic or a paper format, wherein the electronic format is selected from the group consisting of electronic mail, disk, compact disk (CD), digital versatile disk (DVD), memory card, memory chip, ROM or RAM, magnetic optical disk, tape, video, video clip, microfilm, internet, shared network, shared server; wherein the data is displayed, transmitted or analyzed via physical transfer, electronic transmission, video display, or telecommunication; wherein the data is compared and compiled at the site of sampling specimens or at a location where the data is transmitted.

15. A method for inhibiting cancer or precancerous growth in a mammalian tissue, comprising contacting the tissue with an inhibitor of WIP1 protein or a fragment thereof.

16. The method according to claim 15, wherein the cancer or precancerous growth is metastasis.

17. The method according to claim 15, wherein the inhibitor is an antibody that binds to WIP1 protein.

18. The method according to claim 15, wherein the inhibitor is an antagonist to WIP1 protein.

19. The method according to claim 15, wherein the inhibitor is an antagonist to the 12-lipoxygenase activity of WIP1 protein.

20. The method according to claim 15, wherein the inhibitor is a small molecule.

21. The method according to 15, wherein the tissue is selected from the group consisting of breast tissue, lung tissue, prostate tissue, ovarian tissue, and colon tissue.

22. A method for monitoring the efficacy of a therapeutic treatment regimen in a patient, comprising:

measuring at least one of WIP1 mRNA or WIP1 expression levels in a first sample of precancerous or cancer cells obtained from a patient;

administering the treatment regimen to the patient;

measuring at least one of WIP1 mRNA or WIP1 expression levels in a second sample of precancerous or cancer cells from the patient at a time following administration of the treatment regimen; and

comparing at least one of WIP1 mRNA or WIP1 expression levels in the first and the second samples, wherein data showing a decrease in the levels in the second sample relative to the first sample indicates that the treatment regimen is effective in the patient.

23. The method according to claim 22, wherein the precancerous or cancer cells are obtained breast tissue, lung tissue, prostate tissue, ovarian tissue, and colon tissue.

24. The method according to claim 22, wherein the data from measuring or comparing the expression levels is stored in an electronic or a paper format, wherein the electronic format is selected from the group consisting of electronic mail, disk, compact disk (CD), digital versatile disk (DVD), memory card, memory chip, ROM or RAM, magnetic optical disk, tape, video, video clip, microfilm, internet, shared network, shared server; wherein the data is displayed, transmitted or analyzed via physical transfer, electronic transmission, video display, or telecommunication; wherein the data is compared and compiled at the site of sampling specimens or at a location where the data is transmitted.

25. An isolated WIP1 gene amplicon, wherein the amplicon comprises more than one copy of a polynucleotide selected from the group consisting of:

(a) a polynucleotide encoding the polypeptide set forth in SEQ ID NO:2;

(b) a polynucleotide set forth in SEQ ID NO:1;

(c) a polynucleotide having at least about 90% sequence identity to the polynucleotide of (a) or (b); and

(d) a polynucleotide that is overexpressed in tumor cells having at least about 90% sequence identity to the polynucleotide of (a) or (b).

26. The isolated amplicon of claim 25, which comprises a polynucleotide having at least about 90% sequence identity to SEQ ID NO: 1.

27. The isolated amplicon of claim 25, which comprises a polynucleotide having at least about 90% sequence identity to a polynucleotide encoding the polypeptide as set forth in SEQ ID NO:2.

28. The isolated amplicon of claim 25, which comprises a polynucleotide having at least about 95% sequence identity to a polynucleotide encoding SEQ ID NO:2.

29. The isolated amplicon of claim 25, which comprises a polynucleotide encoding the polypeptide set forth in SEQ ID NO:2.

30. The amplicon of claim 25, wherein the polynucleotide comprises SEQ ID NO:1.

31. The amplicon of claim 25, wherein the polynucleotide sequence encodes the polypeptide of SEQ ID NO:2.

32. A method of making a pharmaceutical composition comprising:

a) identifying a compound which is a moduletor of WIP1;

b) synthesizing the compound; and

c) optionally mixing the compound with suitable additives.

33. A method for diagnosing a cancer in a mammal, comprising:

detecting WIP1 protein expression by contacting a biological subject from a region of the mammal that is suspected to be precancerous or cancerous with anti-WIP1 antibody, thereby generating data for a test level; and

comparing the test level to data for a control level, wherein an elevated test level of the biological subject relative to the control level indicates the presence of a cancer or precancerous lesion in the mammal.

34. The method according to claim 33, wherein the biological subject is selected from the group consisting of breast tissue, lung tissue, prostate tissue, ovarian tissue, and colon tissue.

35. The method according to claim 33, wherein the data is stored in an electronic or a paper format, wherein the data is stored in an electronic or a paper format, wherein the electronic format is selected from the group consisting of electronic mail, disk, compact disk (CD), digital versatile disk (DVD), memory card, memory chip, ROM or RAM, magnetic optical disk, tape, video, video clip, microfilm, internet, shared network, shared server; wherein the data is displayed, transmitted or analyzed via physical transfer, electronic transmission, video display, or telecommunication; wherein the data is compared and compiled at the site of sampling specimens or at a location where the data is transmitted.

36. A method of modulating WIP1 activities by contacting a biological subject from a region that is suspected to be precancerous or cancerous with a modulator of the WIP1 protein.

37. A method according to claim 36 wherein the modulator is a small molecule.

38. A method according to claim 36, wherein said modulator partially or completely inhibits transcription of WIP1.